Kalemeera et al. Journal of Pharmaceutical Policy and Practice (2016) 9:5 DOI 10.1186/s40545-016-0054-x
RESEARCH
Open Access
Assessment of the nevirapine safety signal using data from the national antiretroviral dispensing database: a retrospective study Francis Kalemeera1*, Assegid T. Mengistu2 and Johannes Gaeseb3
Abstract Background: Clinical trials showed a higher risk of skin- and liver- related adverse reactions when NVP-based antiretroviral therapy (ART) was initiated in female and male patients with baseline CD4 cell counts ≥250 and ≥400, respectively. Some studies reported no difference in risk between the high and low CD4 count groups. Consequently, the use of NVP-based ART in all patients with a CD4 cell count
RESEARCH
Open Access
Assessment of the nevirapine safety signal using data from the national antiretroviral dispensing database: a retrospective study Francis Kalemeera1*, Assegid T. Mengistu2 and Johannes Gaeseb3
Abstract Background: Clinical trials showed a higher risk of skin- and liver- related adverse reactions when NVP-based antiretroviral therapy (ART) was initiated in female and male patients with baseline CD4 cell counts ≥250 and ≥400, respectively. Some studies reported no difference in risk between the high and low CD4 count groups. Consequently, the use of NVP-based ART in all patients with a CD4 cell count
